Metrics as of 10/17/2026, 08:26 AM (Berlin time), refresh in progress.
Agenus Stock
Agenus Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Garo H. Armen
- Employees
- 81
- Market cap
- $273 M
- IPO
- 08/02/2000
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized…
Agenus stock: price history
1D
-9.6%
1W
-21.3%
1M
-16.2%
6M
+26.1%
YTD
+92.4%
1Y
+51.4%
2Y
+29.1%
5Y
-94.3%
10Y
-94.9%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~17% stronger price swings than usual
Agenus stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Agenus Inc. is a clinical-stage biotechnology company focused on the discovery and development of immuno-oncology therapies. The company utilizes proprietary platform technologies such as Retrocyte Display for antibody expression and QS-21 Stimulon as a vaccine adjuvant. The pipeline comprises a range of therapeutic candidates at various clinical stages, including monoclonal antibodies targeting different immune checkpoints and cancer pathways. The business model is primarily based on generating royalty revenue from strategic partnerships with pharmaceutical companies such as Merck Sharp & Dohme, Gilead Sciences, Inc., and Incyte Corporation.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Ask the agents about Agenus
Analyst assessment of Agenus
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 05/10/2026
Agenus stock metrics
P/E
2.22
P/B
-1.25
EV/EBITDA
1.89
RETURN ON EQUITY
0.3%
NET MARGIN
-1.6%
DEBT/EQUITY
-0.2
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.4%
FLOAT SHARES
39,901,713
AVG. DAILY VOLUME (30D)
1,107,853
Insider transactions (SEC)
HARRISON THOMAS L
ARMEN GARO H
HARRISON THOMAS L
ARMEN GARO H
ARMEN GARO H
Attention
Price since yesterday: -9.6%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Agenus stock
What does Agenus do?
Agenus Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Garo H. Armen, the company employs around 81 people.
The IPO was on 08/02/2000; the stock trades on NASDAQ under the ticker AGEN.
What do analysts say about Agenus stock?
12 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Agenus report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does Agenus pay a dividend?
No, Agenus currently does not pay a dividend.
Which stocks are comparable to Agenus?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Agenus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Agenus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.